GB9800569D0
(en)
*
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
MXPA03002410A
(es)
*
|
2000-09-20 |
2003-06-19 |
Merck Patent Gmbh |
4-amino-quinazolinas.
|
EP1353693B1
(en)
|
2001-01-16 |
2005-03-16 |
Glaxo Group Limited |
Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
|
ES2282673T3
(es)
|
2002-07-15 |
2007-10-16 |
Janssen Pharmaceutica N.V. |
Analogos 3-furanilo de toxoflavina como inhibidores de quinasas.
|
WO2004041274A1
(en)
*
|
2002-11-05 |
2004-05-21 |
Arena Pharmaceuticals, Inc. |
Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof
|
CA2523079C
(en)
*
|
2003-05-02 |
2012-08-14 |
Globopharm Pharmazeutische Produktions-Und Handelsgesellschaft M.B.H. |
Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts
|
CA2529320C
(en)
*
|
2003-06-17 |
2013-03-05 |
Arena Pharmaceuticals, Inc. |
Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases
|
CN1809545A
(zh)
*
|
2003-06-20 |
2006-07-26 |
艾尼纳制药公司 |
N-苯基-哌嗪衍生物和预防或者治疗5HT2c受体相关疾病的方法
|
EP1653986A4
(en)
|
2003-08-01 |
2007-03-14 |
Smithkline Beecham Corp |
TREATMENT OF CANCERS EXPRESSING P95 SP ERBB2 / SP
|
US7501427B2
(en)
|
2003-08-14 |
2009-03-10 |
Array Biopharma, Inc. |
Quinazoline analogs as receptor tyrosine kinase inhibitors
|
MXPA06001767A
(es)
|
2003-08-14 |
2006-05-12 |
Array Biopharma Inc |
Analogos de quinazolina como inhibidores de la tirosina quinasa receptora.
|
TWI258478B
(en)
|
2003-10-31 |
2006-07-21 |
Arena Pharm Inc |
Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
|
CA2549869C
(en)
*
|
2003-12-18 |
2015-05-05 |
Janssen Pharmaceutica N.V. |
Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
|
EP1768963A4
(en)
*
|
2004-06-03 |
2009-06-10 |
Smithkline Beecham Cork Ltd |
CANCER TREATMENT METHOD
|
WO2005120512A2
(en)
*
|
2004-06-04 |
2005-12-22 |
Smithkline Beecham (Cork) Limited |
Cancer treatment method
|
WO2006002422A2
(en)
|
2004-06-24 |
2006-01-05 |
Novartis Vaccines And Diagnostics Inc. |
Compounds for immunopotentiation
|
JP2008511632A
(ja)
*
|
2004-08-27 |
2008-04-17 |
スミスクライン ビーチャム (コーク) リミテッド |
癌治療法
|
GB0427131D0
(en)
*
|
2004-12-10 |
2005-01-12 |
Glaxosmithkline Biolog Sa |
Novel combination
|
SI1833473T1
(sl)
*
|
2004-12-23 |
2010-01-29 |
Arena Pharm Inc |
Sestavki modulatorjev 5HT2C receptorjev in postopki uporabe
|
PL1853250T3
(pl)
*
|
2005-02-18 |
2012-03-30 |
Abraxis Bioscience Llc |
Kombinacje i sposoby podawania środków terapeutycznych oraz terapia skojarzona
|
US8735394B2
(en)
|
2005-02-18 |
2014-05-27 |
Abraxis Bioscience, Llc |
Combinations and modes of administration of therapeutic agents and combination therapy
|
ES2601503T3
(es)
|
2005-04-19 |
2017-02-15 |
Novartis Ag |
Composición farmacéutica
|
BR122018075851B1
(pt)
|
2005-11-15 |
2022-01-11 |
Array Biopharma Inc |
Compostos relacionados ao tratamento de doença hiperproliferativa e processos para preparar compostos
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
TW200808739A
(en)
|
2006-04-06 |
2008-02-16 |
Novartis Vaccines & Diagnostic |
Quinazolines for PDK1 inhibition
|
US20090203718A1
(en)
*
|
2006-04-13 |
2009-08-13 |
Smithkline Beecham (Cork) Ltd. |
Cancer treatment method
|
WO2007124288A1
(en)
|
2006-04-19 |
2007-11-01 |
Novartis Ag |
Indazole compounds and methods for inhibition of cdc7
|
WO2008044045A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
JP5528806B2
(ja)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
EP2103620A1
(en)
|
2006-12-12 |
2009-09-23 |
Takeda Pharmaceutical Company Limited |
Fused heterocyclic compound
|
CN101245050A
(zh)
*
|
2007-02-14 |
2008-08-20 |
上海艾力斯医药科技有限公司 |
4-苯胺喹唑啉衍生物的盐
|
EP2166859A4
(en)
*
|
2007-06-11 |
2011-09-07 |
Smithkline Beecham Cork Ltd |
QUINAZOLINE SALT COMPOUNDS
|
US20110306572A1
(en)
*
|
2007-09-24 |
2011-12-15 |
Tragara Pharmaceuticals, Inc |
COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL InHIBITORS OF EGFR [ErbB1] AND HER-2 [ErbB2]
|
WO2009079541A1
(en)
*
|
2007-12-18 |
2009-06-25 |
Smithkline Beecham (Cork) Limited |
Quinazoline ditosylate anhydrate forms
|
EP2240475B1
(en)
|
2007-12-20 |
2013-09-25 |
Novartis AG |
Thiazole derivatives used as pi 3 kinase inhibitors
|
EP2288585A1
(en)
*
|
2008-03-04 |
2011-03-02 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of intermediates related to the 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine
|
WO2009113560A1
(ja)
|
2008-03-12 |
2009-09-17 |
武田薬品工業株式会社 |
縮合複素環化合物
|
KR20210131473A
(ko)
|
2008-03-18 |
2021-11-02 |
제넨테크, 인크. |
항-her2 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법
|
US20120035183A1
(en)
*
|
2008-03-19 |
2012-02-09 |
Gilmer Tona M |
Cancer Treatment Method
|
US8252805B2
(en)
|
2008-05-07 |
2012-08-28 |
Teva Pharmaceutical Industries Ltd. |
Forms of lapatinib ditosylate and processes for preparation thereof
|
CN101584696A
(zh)
*
|
2008-05-21 |
2009-11-25 |
上海艾力斯医药科技有限公司 |
包含喹唑啉衍生物的组合物及制备方法、用途
|
US20100197915A1
(en)
*
|
2008-08-06 |
2010-08-05 |
Leonid Metsger |
Lapatinib intermediates
|
EP2158912A1
(en)
|
2008-08-25 |
2010-03-03 |
Ratiopharm GmbH |
Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
|
EP2158913A1
(en)
|
2008-08-25 |
2010-03-03 |
Ratiopharm GmbH |
Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
|
WO2010027848A2
(en)
*
|
2008-08-26 |
2010-03-11 |
Teva Pharmaceutical Industries Ltd. |
Forms of lapatinib compounds and processes for the preparation thereof
|
US8664389B2
(en)
|
2008-11-03 |
2014-03-04 |
Natco Pharma Limited |
Process for the preparation of lapatinib and it's pharmaceutically acceptable salts
|
CN101735200B
(zh)
*
|
2008-11-17 |
2013-01-02 |
岑均达 |
喹唑啉类化合物
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
BR112012003653A2
(pt)
|
2009-08-21 |
2016-03-22 |
Smithkline Beecham Cork Ltd |
"método de tratar o câncer."
|
EP2484678B1
(en)
|
2009-09-28 |
2015-01-21 |
Qilu Pharmaceutical Co., Ltd |
4-(substituted anilino)quinazoline derivatives as tyrosine kinase inhibitors
|
US20120245351A1
(en)
*
|
2009-09-29 |
2012-09-27 |
Natco Pharma Limited |
Process for the preparation of lapatinib and its pharmaceutically acceptable salts
|
CN102079759B
(zh)
*
|
2009-12-01 |
2014-09-17 |
天津药物研究院 |
6位取代的喹唑啉类衍生物、其制备方法和用途
|
US20110165155A1
(en)
|
2009-12-04 |
2011-07-07 |
Genentech, Inc. |
Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
|
CN102791715B
(zh)
|
2009-12-31 |
2016-04-27 |
卡洛斯三世国家癌症研究中心基金会 |
用作激酶抑制剂的三环化合物
|
ES2627703T3
(es)
|
2010-01-22 |
2017-07-31 |
Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii |
Inhibidores de PI3·quinasa
|
EP2536720A1
(en)
|
2010-02-18 |
2012-12-26 |
Centro Nacional de Investigaciones Oncológicas (CNIO) |
Triazolo [4, 5 - b]pyridin derivatives
|
US8710221B2
(en)
|
2010-03-23 |
2014-04-29 |
Scinopharm Taiwan, Ltd. |
Process and intermediates for preparing lapatinib
|
PT2550269E
(pt)
|
2010-03-23 |
2016-06-20 |
Scinopharm Taiwan Ltd |
Processo e intermediários para a preparação de lapatinib
|
MX2012011155A
(es)
|
2010-03-29 |
2012-12-05 |
Abraxis Bioscience Llc |
Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
|
MX364637B
(es)
|
2010-03-29 |
2019-05-03 |
Abraxis Bioscience Llc Star |
Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc.
|
WO2011121317A1
(en)
|
2010-04-01 |
2011-10-06 |
Centro Nacional De Investigaciones Oncologicas (Cnio) |
Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
|
EP2560968A4
(en)
*
|
2010-04-22 |
2013-08-28 |
Apotex Pharmachem Inc |
POLYMORPHIC FORMS OF LAPATINIB DITOSYLATE AND METHODS OF PREPARATION THEREOF
|
WO2011146712A1
(en)
*
|
2010-05-21 |
2011-11-24 |
Glaxosmithkline Llc |
Combination
|
US20130072507A1
(en)
|
2010-05-21 |
2013-03-21 |
Glaxosmithkline Llc |
Combination
|
WO2011153049A1
(en)
|
2010-06-02 |
2011-12-08 |
The Trustees Of The University Of Pennsylvania |
Methods and use of compounds that bind to her2/neu receptor complex
|
WO2011153050A1
(en)
|
2010-06-02 |
2011-12-08 |
The Trustees Of The University Of Pennsylvania |
Methods and use of compounds that bind to her2/neu receptor complex
|
US9045431B2
(en)
|
2010-06-02 |
2015-06-02 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of 5-HT2C receptor agonists
|
KR20180049180A
(ko)
|
2010-06-04 |
2018-05-10 |
아브락시스 바이오사이언스, 엘엘씨 |
췌장암의 치료 방법
|
CN102295638B
(zh)
*
|
2010-06-24 |
2014-07-09 |
齐鲁制药有限公司 |
拉帕替尼的制备方法
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
US20130131090A1
(en)
*
|
2010-08-03 |
2013-05-23 |
Bandi Parthasaradhi Reddy |
Salts of lapatinib
|
WO2012030939A1
(en)
|
2010-09-01 |
2012-03-08 |
Arena Pharmaceuticals, Inc. |
Administration of lorcaserin to individuals with renal impairment
|
CN107669687A
(zh)
|
2010-09-01 |
2018-02-09 |
艾尼纳制药公司 |
用于体重控制的5‑ht2c激动剂的调节释放剂型
|
SG188361A1
(en)
|
2010-09-01 |
2013-04-30 |
Arena Pharm Inc |
Non-hygroscopic salts of 5-ht2c agonists
|
CN103189359A
(zh)
|
2010-09-01 |
2013-07-03 |
艾尼纳制药公司 |
5-ht2c激动剂的光学活性酸盐
|
WO2012052745A1
(en)
|
2010-10-21 |
2012-04-26 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
Combinations of pi3k inhibitors with a second anti -tumor agent
|
WO2012069557A1
(en)
|
2010-11-24 |
2012-05-31 |
Glaxo Group Limited |
Multispecific antigen binding proteins targeting hgf
|
WO2012083440A1
(en)
|
2010-12-23 |
2012-06-28 |
Apotex Pharmachem Inc |
A process for the preparation of lapatinib and its ditosylate salt
|
WO2012098387A1
(en)
|
2011-01-18 |
2012-07-26 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
|
UY33883A
(es)
|
2011-01-31 |
2012-08-31 |
Novartis Ag |
Novedosos derivados heterocíclicos
|
SG10201601711SA
(en)
|
2011-03-04 |
2016-04-28 |
Newgen Therapeutics Inc |
Alkyne Substituted Quinazoline Compound And Methods Of Use
|
US9295676B2
(en)
|
2011-03-17 |
2016-03-29 |
The Trustees Of The University Of Pennsylvania |
Mutation mimicking compounds that bind to the kinase domain of EGFR
|
WO2012125913A1
(en)
|
2011-03-17 |
2012-09-20 |
The Trustees Of The University Of Pennsylvania |
Methods and use of bifunctional enzyme-building clamp-shaped molecules
|
ITMI20110480A1
(it)
*
|
2011-03-25 |
2012-09-26 |
F I S Fabbrica Italiana Sint P A |
Procedimento per la preparazione di lapatinib e suoi sali
|
ES2657750T3
(es)
|
2011-04-01 |
2018-03-06 |
Genentech, Inc. |
Combinación de compuesto inhibidor de AKT y vemurafenib para su uso en tratamientos terapéuticos
|
CN102918029B
(zh)
|
2011-05-17 |
2015-06-17 |
江苏康缘药业股份有限公司 |
4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
|
EP2524918A1
(en)
|
2011-05-19 |
2012-11-21 |
Centro Nacional de Investigaciones Oncológicas (CNIO) |
Imidazopyrazines derivates as kinase inhibitors
|
BR112013029711B1
(pt)
|
2011-05-19 |
2020-05-12 |
Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii |
Compostos
|
ITMI20110894A1
(it)
|
2011-05-20 |
2012-11-21 |
Italiana Sint Spa |
Impurezza del lapatinib e suoi sali
|
WO2013004984A1
(en)
|
2011-07-07 |
2013-01-10 |
Centro Nacional De Investigaciones Oncologicas (Cnio) |
Tricyclic compounds for use as kinase inhibitors
|
WO2013005041A1
(en)
|
2011-07-07 |
2013-01-10 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
Tricyclic heterocyclic compounds as kinase inhibitors
|
CN102321076B
(zh)
*
|
2011-07-07 |
2013-08-21 |
中国科学技术大学 |
拉帕替尼中间体及其类似物的制备方法
|
WO2013005057A1
(en)
|
2011-07-07 |
2013-01-10 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
New compounds
|
AP2014007601A0
(en)
|
2011-10-28 |
2014-04-30 |
Novartis Ag |
Novel purine derivatives and their use in the treatment of disease
|
WO2013080218A1
(en)
|
2011-11-28 |
2013-06-06 |
Fresenius Kabi Oncology Ltd. |
Novel intermediates and process for the preparation of lapatinib and its pharmaceutically acceptable salts
|
JP2015506955A
(ja)
|
2012-01-31 |
2015-03-05 |
スミスクライン ビーチャム (コーク) リミテッド |
がんを治療する方法
|
CN105566305B
(zh)
*
|
2012-03-06 |
2018-08-14 |
齐鲁制药有限公司 |
4-(取代苯胺基)喹唑啉衍生物二甲苯磺酸盐的多晶型物及其制备方法和用途
|
US20150297604A1
(en)
|
2012-04-03 |
2015-10-22 |
Novartis Ag |
Combination Products with Tyrosine Kinase Inhibitors and their Use
|
US10213432B2
(en)
|
2012-05-16 |
2019-02-26 |
Novartis Ag |
Dosage regimen for a PI-3 kinase inhibitor
|
US20150297610A1
(en)
|
2012-10-09 |
2015-10-22 |
Arena Pharmaceuticals, Inc. |
Method of weight management
|
CZ2012712A3
(cs)
|
2012-10-17 |
2014-04-30 |
Zentiva, K.S. |
Nový způsob výroby klíčového intermediátu výroby lapatinibu
|
CN103819462B
(zh)
*
|
2012-11-19 |
2017-07-25 |
齐鲁制药有限公司 |
一种药用盐及其制备方法和用途
|
CN105732596B
(zh)
*
|
2012-11-19 |
2019-05-28 |
齐鲁制药有限公司 |
N-[3-氯-4-(3-氟苄氧基)苯基]-6-[5-[[2-(甲亚磺酰基)乙基]氨基]甲基]-2-呋喃基]-4-喹唑啉胺多晶型物及其制备方法
|
CN103819461B
(zh)
*
|
2012-11-19 |
2016-06-15 |
齐鲁制药有限公司 |
N-[3-氯-4-(3-氟苄氧基)苯基]-6-[5-[[2-(甲亚磺酰基)乙基]氨基]甲基]-2-呋喃基]-4-喹唑啉胺多晶型物及其制备方法
|
CN103896926A
(zh)
*
|
2012-12-27 |
2014-07-02 |
上海创诺医药集团有限公司 |
二对甲苯磺酸拉帕替尼溶剂化物多晶型物及其制法和用途
|
US9024023B2
(en)
|
2013-01-14 |
2015-05-05 |
F.I.S.—Fabbrica Italiana Sintetici S.p.A. |
Efficient process for the preparation of lapatinib and salts thereof by means of new intermediates
|
ITVI20130003A1
(it)
|
2013-01-14 |
2014-07-14 |
F I S Fabbrica Italiana Sint I S P A |
Procedimento per la preparazione di lapatinib e suoi sali mediante nuovi intermedi.
|
ES2635620T3
(es)
|
2013-02-19 |
2017-10-04 |
Hexal Ag |
Composición farmacéutica que comprende n-[3-cloro-4-(3-fluorobenciloxi)fenil]-6-[5({[2-(metilsulfonil)etil]amino} metil)-2-furil]quinazolin-4-amina o una sal, solvato o sal solvatada farmacéuticamente aceptables de la misma
|
CN103159747A
(zh)
*
|
2013-02-26 |
2013-06-19 |
常州鸿创高分子科技有限公司 |
一种二对甲苯磺酸拉帕替尼的合成方法
|
US9468681B2
(en)
|
2013-03-01 |
2016-10-18 |
California Institute Of Technology |
Targeted nanoparticles
|
WO2014170910A1
(en)
|
2013-04-04 |
2014-10-23 |
Natco Pharma Limited |
Process for the preparation of lapatinib
|
CN104098517A
(zh)
*
|
2013-04-09 |
2014-10-15 |
上海科胜药物研发有限公司 |
一种制备拉帕替尼中间体的方法
|
HU231012B1
(hu)
|
2013-05-24 |
2019-11-28 |
Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság |
Lapatinib sók
|
CN105979947A
(zh)
|
2013-12-06 |
2016-09-28 |
诺华股份有限公司 |
α-同工型选择性磷脂酰肌醇3-激酶抑制剂的剂量方案
|
CN104788434A
(zh)
*
|
2014-01-16 |
2015-07-22 |
江苏恒瑞医药股份有限公司 |
一种蛋白酪氨酸激酶抑制剂的二苯磺酸盐
|
WO2015128837A1
(en)
|
2014-02-26 |
2015-09-03 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Methods of treating cancer patients responding to ezh2 inhibitor gsk126
|
EP2937346A1
(en)
|
2014-04-24 |
2015-10-28 |
F.I.S.- Fabbrica Italiana Sintetici S.p.A. |
Co-crystals of lapatinib
|
ES2855075T3
(es)
|
2014-10-17 |
2021-09-23 |
Novartis Ag |
Combinación de ceritinib con un inhibidor de EGFR
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
WO2017003668A1
(en)
|
2015-07-01 |
2017-01-05 |
California Institute Of Technology |
Cationic mucic acid polymer-based delivery systems
|
EP3330267B1
(en)
|
2015-07-29 |
2022-01-05 |
Shionogi & Co., Ltd. |
Salt of quinazoline derivative or crystal thereof, and method for producing salt of quinazoline derivative or crystal thereof
|
EP3331919A1
(en)
|
2015-08-07 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination therapy comprising anti ctla-4 antibodies
|
CN108472289A
(zh)
|
2015-11-02 |
2018-08-31 |
诺华股份有限公司 |
磷脂酰肌醇3-激酶抑制剂的给药方案
|
BR112018011228A2
(pt)
|
2015-12-01 |
2019-01-15 |
Glaxosmithkline Ip Dev Ltd |
tratamentos de combinação e seus usos e métodos
|
CN106892898B
(zh)
*
|
2015-12-18 |
2021-02-05 |
陕西师范大学 |
氮杂糖衍生化的喹唑啉类化合物
|
RU2603943C1
(ru)
*
|
2016-02-01 |
2016-12-10 |
Индивидуальный предприниматель Михайлов Олег Ростиславович |
КРИСТАЛЛИЧЕСКАЯ γ-МОДИФИКАЦИЯ N-{3-ХЛОР-4-[(3-ФТОРБЕНЗИЛ)ОКСИ] ФЕНИЛ}-6-[5-({[2-(МЕТАНСУЛЬФОНИЛ)ЭТИЛ]АМИНО}МЕТИЛ)-2-ФУРИЛ]-4-ХИНАЗОЛИНАМИНА БИС (4-МЕТИЛБЕНЗОЛСУЛЬФОНАТА) МОНОГИДРАТА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЁ ОСНОВЕ
|
EP3266773B1
(en)
|
2016-07-04 |
2018-04-11 |
F.I.S.- Fabbrica Italiana Sintetici S.p.A. |
Process for the preparation of lapatinib ditosylate monohydrate by means of an improved crystallization procedure
|
US11649289B2
(en)
|
2016-08-04 |
2023-05-16 |
Glaxosmithkline Intellectual Property Development Limited |
Anti-ICOS and anti-PD-1 antibody combination therapy
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
CN110430881A
(zh)
|
2017-01-30 |
2019-11-08 |
盐野义制药株式会社 |
含有喹唑啉衍生物的固体制剂
|
JP2021506974A
(ja)
|
2017-12-18 |
2021-02-22 |
スターングリーン、インク. |
チロシンキナーゼ阻害剤として有用なピリミジン化合物
|
WO2020160365A1
(en)
|
2019-02-01 |
2020-08-06 |
Glaxosmithkline Intellectual Property Development Limited |
Belantamab mafodotin in combination with pembrolizumab for treating cancer
|
MX2021015651A
(es)
|
2019-06-26 |
2022-06-14 |
Glaxosmithkline Ip Dev Ltd |
Proteinas de union a la proteina accesoria del receptor de interleucina-1 (il1rap).
|
WO2021043961A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
|
WO2021046293A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab
|
US20230067202A1
(en)
|
2020-01-28 |
2023-03-02 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Treatments and Uses and Methods Thereof
|